Computer model to predict who responds to kidney nerve treatment for high blood pressure
Tests a digital twin model predicting treatment response in adults with hypertension.
Plain-language title generated from the registry record
Registry title: Virtual Twins as Tools for Personalized Clinical Care in Renal Denervation - Pilot Study
Key facts
- Where
- Paris, FranceSee the 2 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with high blood pressure in three groups: people with a clinical need for renal denervation, people with untreated primary hypertension starting medicine, and people with primary aldosteronism planned for adrenal gland surgery.
- Age
- 18 to 90 years
- Sex
- All sexes can join.
- Disease stage
- Hypertension in one of three groups: a clinical indication for renal denervation (a procedure on the kidney nerves), untreated primary hypertension (office blood pressure above 140/90 mmHg) starting treatment, or confirmed primary aldosteronism with a clinical indication for surgery to remove one adrenal gland.
- Earlier treatment
- Renal denervation group: stable treatment for at least 1 month. Untreated hypertension group: no blood pressure medicine, or continuous treatment for less than 6 months.
- Biomarker or test result
- Primary aldosteronism confirmed according to current guidelines (surgery group only).
Main reasons for not taking part
- Pregnancy
- Skin irritation or non-intact skin where sensors are attached (breastbone, chest, finger)
- Known allergy to ultrasound gel, adhesives, Ag/AgCl electrodes, metals or plastics
Read by machine on 13 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Source: NCT07462572, who can take part
Where in France
- Hypertension Unit - Georges Pompidou European HospitalParis, FranceContact: Laurence AMARNo longer taking part
- Pharmacology Unit - Georges Pompidou European HospitalParis, FranceContact: Rosa Maria BRUNONo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Trial code
- NCT07462572
- Record updated
- 10 March 2026
- Original description
High blood pressure (hypertension) is a common condition. Despite the availability of several medications, many patients continue to have poorly controlled blood pressure. Renal denervation (RDN), a minimally invasive procedure that reduces overactive kidney nerves, has emerged as a potential treatment for certain patients with difficult-to-control hypertension. However, not all patients benefit from this procedure, and there is currently no reliable way to predict who will respond.Read full original descriptionShow less
Virtual Twins as Tools for Personalized Clinical Care in Renal Denervation - Pilot Study
High blood pressure (hypertension) is a common condition. Despite the availability of several medications, many patients continue to have poorly controlled blood pressure. Renal denervation (RDN), a minimally invasive procedure that reduces overactive kidney nerves, has emerged as a potential treatment for certain patients with difficult-to-control hypertension. However, not all patients benefit from this procedure, and there is currently no reliable way to predict who will respond.
The VITAL-RDN study (Virtual twins as tools for personalized clinical care in renal denervation - Pilot study) aims to test whether a "digital twin" can help predict which patients are most likely to respond to renal denervation. A digital twin is a personalized computer model built from an individual patient's clinical, biological, and physiological data. It is designed to simulate how that patient's cardiovascular system functions and how it may respond to treatment.
The main objective of this pilot study is to evaluate whether the digital twin can accurately distinguish between patients who will respond to renal denervation and those who will not. A responder is defined as a patient whose daytime systolic blood pressure decreases by at least 5 mmHg three months after the RDN.
Three groups of patients will be enrolled:
30 patients with resistant hypertension or other clinical indications for renal denervation.
20 patients with untreated primary hypertension who are starting blood pressure-lowering medication.
10 patients with primary aldosteronism who are scheduled for surgical adrenalectomy.
In addition to evaluating prediction of response to renal denervation, the study will also assess the performance of the digital twin in predicting response to antihypertensive medication or adrenalectomy in the respective subgroups.
If successful, this approach could support more personalized treatment decisions, reduce unnecessary procedures, and improve blood pressure control by matching the right therapy to the right patient.
Exclusion: Known allergies to ultrasound gel, adhesives, Ag/AgCl electrodes, metals, or plastics; Pregnancy; Presence of skin irritation or non-intact skin at sensor attachment sites (sternum, chest, finger) preventing the possibility to pose sensors.
General inclusion criteria:; Age between 18 and 90 years for both sexes; Patient information and verbal non-opposition expressed by the patient, recorded in writing on the non-opposition form by the investigator; Patients affiliated with social security or an equivalent scheme; Specific inclusion criteria:; Patients with clinical indication for RDN:; Stable treatment for at least 1 month; Clinical indication for RDN according to current recommendations or clinical judgment, as part of routine care; Patients with untreated primary hypertension:; Treatment-naïve hypertensive patients or continuous antihypertensive treatment for < 6 months; Office BP >140/90 mmHg in repeated measures or office BP >140/90 mmHg in a single visit and home BP or daytime 24h-ABPM BP >135/85 mmHg; Clinical indication to start antihypertensive treatment; Patients with clinical indication to surgical adrenalectomy:; Confirmed diagnosis of primary aldosteronism according to current guidelines; Clinical indication for monoliteral surgical adrenalectomy.